FAB-MS, magnetic susceptibility, CV and X-ray diffraction establish [Re(9S3)2]2+ (9S3=1,4,7-trithiacyclononane) as the first homoleptic thioether complex of Re, a compound of potential utility in cancer therapy.
FAB-MS, magnetic susceptibility, CV and X-ray diffraction establish [Re(9S3)2]2+ (9S3=1,4,7-trithiacyclononane) as the first homoleptic thioether complex of Re, a compound of potential utility in cancer therapy.